Synchron Inc.
Endovascular neural interface could help paralyzed patients
This article was originally published in Start Up
Executive Summary
Synchron Inc. is developing what it believes is the first minimally invasive implantable brain device that could help paralyzed patients: its neural interface, Stentrode, consists of an electrode array built onto a self-expanding stent that is implanted in a cerebral blood vessel. Once the stent is implanted, the array is designed to record local neuronal activity, then translate that activity into a signal that could be used to manipulate mobility-assist devices and return movement to the paralyzed user.
You may also be interested in...
Outlook 2023: Market Experts On Importance Of Value, Mental Health In A ‘World On Fire’
Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.
Keeping Track: Two Targeted Oncologics And A Novel SGLT-2 Inhibitor Clear US FDA
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Health And Wellness Weekly Trademarks Review: 24 January
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.